Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
42.63
+0.68 (+1.62%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
33
34
Next >
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
March 15, 2023
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D...
Via
Benzinga
GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
March 14, 2023
From
GSK plc
Via
Business Wire
3 High Dividend Stocks With Attractive Total Return Potential
March 10, 2023
In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns.
Via
InvestorPlace
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
March 08, 2023
These companies aren't working on a vaccine, but a monoclonal antibody.
Via
Investor's Business Daily
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
March 08, 2023
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
GSK CEO Emma Walmsley On Beating Q4 Earnings
February 01, 2023
GSK came out with quarterly earnings of $0.64 per share.
Via
Talk Markets
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?
March 05, 2023
This vaccine candidate could help tackle the respiratory syncytial virus.
Via
The Motley Fool
March 2023 Stock Considerations
March 04, 2023
The calendar has turned, and a new trading month is upon us. 2023 is flying by as two months are already in the books, and that fact simply highlights the importance of staying invested in the stock...
Via
Talk Markets
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK's Candidate Soon After Pfizer's
March 02, 2023
Via
Benzinga
3 Crucial Things to Know About Moderna Right Now
February 27, 2023
This vaccine leader is preparing for a post-pandemic world.
Via
The Motley Fool
GSK's Relief For Few Months, First Trial Claiming Zantac Caused Cancer Pushed Into Late 2023
February 24, 2023
The first scheduled trial expected next week, related to GSK Plc's (NYSE: GSK) Zantac associated with cancer, has been postponed, likely by several months.
Via
Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields
February 23, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine
February 01, 2023
Via
Benzinga
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
February 23, 2023
Via
Benzinga
Intel and 9 Other Companies With Dividend Cuts in 2023
February 22, 2023
Intel announced that it would cut its dividend by a whopping 66%. Here are nine other companies that have also seen dividend cuts this year.
Via
InvestorPlace
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
February 22, 2023
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END
Via
FinancialNewsMedia
My 3 Biggest Stock Market Predictions for March
February 21, 2023
These three trends will likely drive revenue and share prices.
Via
The Motley Fool
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue
February 15, 2023
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among...
Via
Benzinga
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
February 15, 2023
Via
Benzinga
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out
February 14, 2023
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.
Via
Benzinga
Dividend Income Update For January 2023
February 12, 2023
Without rehashing the wild ride we experienced in the market over the last few months, I could find comfort in one thing: my dividends (even if dividend cuts are on the table these days). Let's see how...
Via
Talk Markets
Week In Review: CANbridge In-Licenses Gene Therapy For Rare Disease From UMass
February 11, 2023
CANbridge Pharma exercised an option for global rights to a novel second-gen gene therapy from UMass Chan medical school. Additionally, Zhimeng Biopharma signed an agreement to out-license global...
Via
Talk Markets
FDA AdComm Votes In Favor Of GSK's Jemperli Single Arm Trial Plan For Rectal Cancer Setting
February 10, 2023
Via
Benzinga
FDA Grants Complete Approval For GSK's Jemperli For Endometrial Cancer
February 10, 2023
Via
Benzinga
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Via
MarketBeat
Topics
ETFs
February 2023 Stock Considerations
February 05, 2023
With a new trading month already in full swing, it is time to highlight some of my potential stock purchases. While the market had a nice bounce in recent months, there is still no shortage of stocks...
Via
Talk Markets
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
February 03, 2023
The major indexes continued to run despite mixed-to-weak earnings.
Via
Investor's Business Daily
FDA Approves First Oral Treatment For Anemia Due To Chronic Kidney Disease
February 02, 2023
Via
Benzinga
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report
February 01, 2023
Two of the three companies easily beat sales and earnings expectations, but sales fell for the third.
Via
Investor's Business Daily
Earnings Scheduled For February 1, 2023
February 01, 2023
Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion.
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.